

- [Investor Presentation](#)
- [Events](#)
- [Earnings Calls & Releases](#)
- [SEC Filings](#)
- [Annual Meeting & Reports](#)
- [Corporate Governance](#)
- [Investor Resources](#)



- [Investor Presentation](#)
- [Events](#)
- [Earnings Calls & Releases](#)
- [SEC Filings](#)
- [Annual Meeting & Reports](#)
- [Corporate Governance](#)
- [Investor Resources](#)

By developing new capabilities in near-patient diagnosis, monitoring and health management, Alere Inc. enables individuals to take charge of improving their health and quality of life. A global leader in rapid point-of-care diagnostics, our products, as well as our new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Being a leading developer of innovative diagnostic and monitoring devices, allows us to combine near patient monitoring tools with value-added healthcare services in order to improve care and lower healthcare costs for both providers and patients.

Our stock is listed on the New York Stock Exchange under the following symbols:

ALR – Common Stock, \$.001 par value

ALR.PR.B – Series B Perpetual Convertible Preferred Stock, \$.001 par value

ALR 16 – 9% Senior Subordinated Notes Due May 15, 2016

For further information please contact Doug Guarino at the following toll free number: 888-872-8679.